Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (55198)	4/8/1999 2:19:00 PM
From: Dave Feldman	Read Replies (1) \| Respond to of 132070

Drug stocks are way too high for my blood, too. I have to admit, though, that GHS's positions in conventional big pharmaceuticals has helped cushion its (and HQH/HQL's) biotech holdings over the past several years. So in this case, my inertia has helped. Haven't put new money into GHS for a long time, but when the discount gets high, I occasionally still put a little more money into HQH or HQL. It wasn't that long ago that I bought J&J in the low-teens PE and Rhone-Poulenc-Rorer for a single-digit PE. Now you can only find values like these in small-cap non-tech companies, those stupid enough to have some earnings and thus incur the wrath of analysts these days. DF